AlphaMab Oncology is at the forefront of developing innovative biotherapeutics, particularly in the realm of cancer treatment. The company has established several proprietary technology platforms, including bispecific antibodies and antibody-drug conjugates (ADCs), which are designed to target multiple signaling pathways involved in complex diseases like cancer. Notably, their bispecific antibody KN046 targets both PD-L1 and CTLA-4, enhancing the immune response against tumors while demonstrating a favorable safety profile. Additionally, their anti-HER2 bispecific antibody, KN026, utilizes a unique platform called CRIB (Charge Repulsion Induced Bispecific) to effectively block HER2 signaling, showing superior efficacy compared to existing therapies. These advancements highlight AlphaMab's commitment to creating differentiated and clinically valuable drugs that address unmet medical needs.

The company also emphasizes the importance of robust manufacturing capabilities, having established state-of-the-art cGMP production facilities to ensure the quality and consistency of their biologics. Their innovative pipeline includes several investigational drugs, such as Envafolimab (KN035), which is the first subcutaneously administered PD-L1 antibody, designed to improve patient compliance and convenience. Furthermore, AlphaMab's proprietary glycan-specific conjugation platform enhances the stability and therapeutic window of their ADCs, such as JSKN003, which targets HER2-positive tumors. Overall, AlphaMab Oncology's focus on differentiated technologies and a strong pipeline positions it as a competitive player in the global biopharmaceutical landscape.

China

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

AlphaMab Oncology

Company Details